Rictor/mTORC2 Drives Progression and Therapeutic Resistance of <i>HER2</i> -Amplified Breast Cancers
Meghan M. Joly(UL Research Institutes), Rebecca S. Cook(Vanderbilt University), Dos D. Sarbassov(Nazarbayev University), William J. Muller(McGill University Health Centre), Violeta Sánchez(Vanderbilt University), Donna J. Hicks(Vanderbilt University), Dana M. Brantley‐Sieders(Susan G. Komen Breast Cancer Foundation), Christian D. Young(Raptamer Discovery Group (United States)), Brent N. Rexer(Vanderbilt University Medical Center), Michelle M. Williams(University of Pittsburgh), Bayley A. Jones(University of Alabama at Birmingham), Mónica V. Estrada(Vanderbilt University)
Cited by 83
Related Papers
Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene
|Cell|1988|1.2k
Coexpression of MMTV/v-Ha-ras and MMTV/c-myc genes in transgenic mice: Synergistic action of oncogenes in vivo
|Cell|1987|799
Melanoma-specific MHC-II expression represents a tumour-autonomous phenotype and predicts response to anti-PD-1/PD-L1 therapy
|Nature Communications|2016|580
Oncogenes and Tumor Suppressor Genes
|Cold Spring Harbor Perspectives in Biology|2010|504
Activation of Akt (Protein Kinase B) in Mammary Epithelium Provides a Critical Cell Survival Signal Required for Tumor Progression
|Molecular and Cellular Biology|2001|279